-+ 0.00%
-+ 0.00%
-+ 0.00%

Actinium Pharmaceuticals highlights Iomab-ACT clinical results in CAR T-cell therapy at ASH 2026

PUBT·11/04/2026 14:17:03
Listen to the news
Actinium Pharmaceuticals highlights Iomab-ACT clinical results in CAR T-cell therapy at ASH 2026
  • Actinium Pharmaceuticals released three Iomab-ACT clinical abstracts for presentation at the 2026 American Society of Hematology meeting.
  • Memorial Sloan Kettering findings suggest potential for immune-cell depletion before investigational CAR T-cell therapy while preventing severe inflammatory and neurological toxicities.
  • A Phase 1b/2 trial evaluates Iomab-ACT conditioning before commercial CD19-directed CAR T-cell therapy, extending development beyond investigational treatments.
  • Preliminary severe sickle cell disease findings explore chemotherapy-free conditioning for donor engraftment; presentation is scheduled for December 13, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611040911PR_NEWS_USPR_____NY88516) on November 04, 2026, and is solely responsible for the information contained therein.